2018 Arizona United Rheumatology Alliance Annual Meeting
OVERVIEW
2018 Arizona United Rheumatology Alliance (AURA) Annual Meeting is organized by Arizona United Rheumatology Alliance (AURA) and will be held during Jun 01 - 03, 2018 at Enchantment Resort, Sedona, Arizona, United States of America.
The target audience for this medical event is Rheumatologists. This CME Conference has been approved for a maximum of 6.00 AMA PRA Category 1 Credits.
Course Objectives:
• Review the clinical features of myositis classification as it relates to myositis-associated autoantibodies.
• Explain the spectrum of selected autoantibodies seen in patients with myositis and their clinical associations.
• Discuss selected treatment aspects of myositis and autoimmune ILD.
• Review the risk of coccidioidomycosis infection in the rheumatic population.
• Review screening habits and how they relate to the 2016 IDSA guidelines for patients with coccidioidomycosis infection.
• Discuss research since 2016 relating to screening and treatment of patients with coccidioidomycosis infection.
• Identify the treatment and management of infected patients with coccidioidomycosis.
• Describe the clinical presentation of auotinflammatory bone disorders.
• Learn what disorders are associated with sterile osteomyelitis.
• Describe the current genetic syndromes that have sterile osteomyelitis/osteitis as a phenotype.
• Define how cannabis produces its pharmacological effects in the body (role and localization of cannabinoid receptors).
• Identify the primary components and functions of the endogenous cannabinoid system.
• Discuss potential benefits and risks of cannabis-based medicines, especially as it pertains to the field of rheumatology.
• Define the role of real-world data and health informatics to support clinical care and research.
• Compare & contrast strengths and limitations of various healthcare-related data sources, tools, and approaches to working with digital information.
• Discuss the current state of clinical trials for lupus and which agents are now in the pipeline.
• Review the use of metrics and measurements in assessing lupus activity.
• Review when to consider using biologics and targeted therapies that are currently available to treat lupus patients.
• Describe the challenges and opportunities related to data linkages and integration of digital data into traditional health care & research settings across a variety of rheumatology use cases.
• Recognize the common infectious triggers of MAS.
• Discuss the genetic predispositions for developing MAS.
• Discuss treatment strategies for MAS.
• Explain what a pharmacy benefit manager (PBM) does.
• Describe what the rebate system is and how it affects formularies for PBMs.
• Identify what step edits and nonmedical switching are and how they are a result of the rebate system.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Rheumatologists. This CME Conference has been approved for a maximum of 6.00 AMA PRA Category 1 Credits.
Course Objectives:
• Review the clinical features of myositis classification as it relates to myositis-associated autoantibodies.
• Explain the spectrum of selected autoantibodies seen in patients with myositis and their clinical associations.
• Discuss selected treatment aspects of myositis and autoimmune ILD.
• Review the risk of coccidioidomycosis infection in the rheumatic population.
• Review screening habits and how they relate to the 2016 IDSA guidelines for patients with coccidioidomycosis infection.
• Discuss research since 2016 relating to screening and treatment of patients with coccidioidomycosis infection.
• Identify the treatment and management of infected patients with coccidioidomycosis.
• Describe the clinical presentation of auotinflammatory bone disorders.
• Learn what disorders are associated with sterile osteomyelitis.
• Describe the current genetic syndromes that have sterile osteomyelitis/osteitis as a phenotype.
• Define how cannabis produces its pharmacological effects in the body (role and localization of cannabinoid receptors).
• Identify the primary components and functions of the endogenous cannabinoid system.
• Discuss potential benefits and risks of cannabis-based medicines, especially as it pertains to the field of rheumatology.
• Define the role of real-world data and health informatics to support clinical care and research.
• Compare & contrast strengths and limitations of various healthcare-related data sources, tools, and approaches to working with digital information.
• Discuss the current state of clinical trials for lupus and which agents are now in the pipeline.
• Review the use of metrics and measurements in assessing lupus activity.
• Review when to consider using biologics and targeted therapies that are currently available to treat lupus patients.
• Describe the challenges and opportunities related to data linkages and integration of digital data into traditional health care & research settings across a variety of rheumatology use cases.
• Recognize the common infectious triggers of MAS.
• Discuss the genetic predispositions for developing MAS.
• Discuss treatment strategies for MAS.
• Explain what a pharmacy benefit manager (PBM) does.
• Describe what the rebate system is and how it affects formularies for PBMs.
• Identify what step edits and nonmedical switching are and how they are a result of the rebate system.
Additional details will be posted as soon as they are available.
KEY DATES
01 Jun, 2018
Event Start Date
03 Jun, 2018
Event End Date
SPECIALITIES
RheumatologySUGGESTED HOTELS
CONFERENCE VENUE
Enchantment ResortRELATED CONFERENCES & LIVE WEBINARS
Quick Links